How to read a peptide study
Reviewed 15 sourcesPublished by PepVault
How to read a peptide study in ten minutes: the species, how many people, the placebo group, the registered outcome, and what "significant" really means.

- Last reviewed
- Sources
- 15
- Questions
- 8
- Compounds
- 3
The short answer
Check five things in this order: the species (cells, rats or people), how many people were in each group, whether a placebo group was compared, whether the trial was registered before it started, and the effect beside the placebo group's. "Significant" (p < 0.05) means a result this large would be unusual if the treatment did nothing. It says nothing about how big or how important the effect is.
Evidence: A method guide built on the CONSORT and ARRIVE reporting standards, the American Statistical Association's statement on p-values and the FDA's phase definitions; every example is a published study.

What do you need to read a study?
Ten minutes and three free pages. The abstract alone answers most of the questions below, if you know where each answer sits.
What you need
- The PubMed record. It shows the abstract, and under it, for papers indexed in MEDLINE, the record's publication types and MeSH terms, the subject tags that include the species studied1.
- The full text, if it is free. Many records link to a free copy in PubMed Central.
- The trial's registry record. CONSORT, the reporting standard for trials, asks every trial report to name its registry and number (NCT and eight digits for ClinicalTrials.gov), often printed at the end of the abstract4. It opens the plan the researchers filed in public.

What should you check, and in what order?
Work down the abstract in the order you meet things on the page. Each step takes under a minute.
- Scroll under the abstract to the publication types and MeSH terms. Randomized Controlled Trial is a trial in which chance decides who gets the treatment and who gets the comparison; Animals with Rats marks an animal study12. A missing tag proves nothing on its own, since publishers supply some publication types and some records are never indexed for MEDLINE1.
- Read the first line of the methods and name the species: cells in a dish (in vitro), live animals (in vivo), or people. If it is not people, read the result as a lead to follow, not as an effect in you.
- Find how many were in each group, not just the total. Reporting standards ask for the exact number per group and how that number was chosen34; an abstract that gives no number has not shown you the base for its conclusion.
- Find the comparison group. Look for the words placebo (a dummy treatment), randomized and double-blind (usually meaning neither the participants nor the researchers knew who got what; CONSORT asks reports to say exactly who was blinded)4. With none of the three, the result cannot tell the treatment apart from time, expectation or chance.
- Find the primary outcome, the main result the study was set up to measure, fixed in advance; some trials name two4. Check that the headline result is that outcome, not a secondary one picked afterwards.
- Open the registry number and compare. The registered primary outcome should match the paper's, and the date of registration should come before the first patient was enrolled414.
- Read the effect as a number beside the placebo group's number, with its confidence interval (the range of effects the data are compatible with).
- Read the p-value last. It tells you how surprising the result would be if the treatment did nothing, never how large or how important the effect is5.
- Read the funding line and who ran the study, so you know whose drug it is.

Why does the species matter?
Most of BPC-157's evidence comes from animals: a 2025 systematic review for sports medicine counted 35 preclinical studies and 1 clinical study15. A 2003 study from the University of Zagreb cut the Achilles tendon of rats and gave BPC-157 or saline daily. Over 14 days of tests the treated tendons carried more load before failing, the rats walked better, and the gap between the cut ends was smaller7. PubMed tags it Animals, Rats and Rats, Wistar, and its abstract does not say how many rats were in each group.
ARRIVE, the reporting standard for animal research, puts that number in its "Essential 10": the exact number of animals in each group and how it was decided3. The same list asks for the species, strain, sex and age3. ARRIVE calls the Essential 10 the basic minimum, since without them readers cannot confidently judge whether the findings are reliable3.
A good rat result is where human testing starts. The tirzepatide trial SURMOUNT-1 is tagged Humans, Randomized Controlled Trial and Clinical Trial, Phase III11. It is the step that rat result has not yet taken.
- In the PepVault app, each compound's library page carries a Research basis row (Established, Moderate or Emerging) that opens to one line on what it means. BPC-157 reads Emerging; tirzepatide reads Established.
How many people is enough?
It depends on the phase. The FDA describes phase 1 studies as 20 to 100 people, testing safety and dosage; phase 2 as up to several hundred, testing efficacy and side effects; and phase 3 as 300 to 3,000, built to show whether a treatment works and to catch less common side effects6. Phase 2 studies, in the FDA's words, "aren't large enough to show whether the drug will be beneficial"6.
| Study | People | Comparison group | Length |
|---|---|---|---|
| BPC-157 knee pain, 20218 | 16 (12 on BPC-157 alone) | None; a chart review with a phone survey | Most injected 6 to 12 months before the call |
| BPC-157 interstitial cystitis, 20249 | 12 women | None | One procedure |
| Semaglutide, STEP 1, 202110 | 1,961 | Placebo, randomized 2:1, double-blind | 68 weeks |
| Tirzepatide, SURMOUNT-1, 202211 | 2,539 | Placebo, randomized 1:1:1:1, double-blind | 72 weeks |
| Semaglutide, SELECT, 202312 | 17,604 | Placebo, randomized 1:1, double-blind | About 40 months of follow-up |
PubMed tags the two BPC-157 pilots as Journal Article only, with Retrospective Studies on the knee study and Pilot Projects on the bladder one89. Neither abstract gives a registry number. Small and uncontrolled is how new treatments are often first tried, and a striking pilot is a reason for a proper trial. It is not that trial.
What does a placebo group change?
It shows how much of the result would have happened anyway. In STEP 1, people on placebo also lost weight: 2.4% of their body weight over 68 weeks, against 14.9% on semaglutide, a difference of 12.4 percentage points10. In SURMOUNT-1, 35% of the placebo group lost 5% or more of their weight11. Without those groups, all of that loss would have been credited to the drug.

The knee pilot shows the other side. Most patients were called six months to a year after their injection and asked to rate their own pain, and the authors write that no specific tools were used to measure their improvement in function or quality of life8. With no comparison group, a knee that healed on its own and one the peptide helped look the same.
What does "significant" mean in a study?
A p-value measures how surprising the results would be if the treatment did nothing. Below 0.05 is the usual line for "statistically significant". The American Statistical Association's 2016 statement sets out what it does not mean: a p-value does not measure the probability that the hypothesis is true or that the data came from chance alone, does not measure the size of an effect or the importance of a result, and decisions should not rest only on whether it passes a threshold5.
So read the effect first. STEP 1 reports P<0.001 for its difference; the informative part is the number beside it, 12.4 points with a 95% confidence interval of 11.5 to 13.4 points10. A narrow interval like that means a precise estimate.
The word also appears in plain-English use. The knee pilot reports that 11 of 12 patients had "significant improvement"8, and the abstract reports no statistical test behind it: there it is the patients' own description.
Is a 20% lower risk the same as 20 fewer people?
No, and the gap is often large. In SELECT, a heart attack, stroke or cardiovascular death happened to 6.5% of people on semaglutide and 8.0% on placebo, a hazard ratio (the event rate on the drug divided by the rate on placebo) of 0.8012. That ratio is the headline "20% lower risk", a relative number. The absolute difference is 1.5 percentage points over a mean of about 40 months: roughly one fewer event for every 67 people treated.

Both numbers are true, and they answer different questions. That is why the CONSORT 2025 standard for reporting trials asks for both the absolute and the relative effect for any yes-or-no outcome4. When a summary gives only the percentage cut, look for the two group rates in the abstract.
Was the trial registered before it started?
A registry record is the plan, filed in public before the results exist. CONSORT asks every trial report to give the registry, the number and the date of registration4, and the medical journal editors' committee (ICMJE) requires registration at or before the first patient's enrollment14. SURMOUNT-1's record, NCT04184622, was first posted on December 3, 2019, the day before the trial's start date, and today it names two primary outcomes: percent change in body weight and the share reaching at least a 5% reduction, both at week 7213. The paper reports exactly those two as its coprimary end points11.
That match is what you look for. A primary outcome that changed between the record and the paper, or a record posted after the results, is a reason to read the result more carefully.
If a study makes you want to start, stop or change a medicine, take the paper to your doctor or pharmacist first.
Sources
- National Library of Medicine. PubMed Help: article type filters, species filters and the Abstract page. pubmed.ncbi.nlm.nih.gov
- National Library of Medicine. Publication characteristics (publication types) with scope notes. nlm.nih.gov
- Percie du Sert N et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020. PubMed 32663219
- Hopewell S et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025. PubMed 40228833
- American Statistical Association. News release, March 7, 2016: the six principles of its statement on statistical significance and p-values (Wasserstein RL, Lazar NA. Am Stat. 2016;70(2):129-133). amstat.org
- U.S. Food and Drug Administration. The drug development process, step 3: clinical research. fda.gov
- Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PubMed 14554208
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PubMed 39325560
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. PubMed 37952131
- ClinicalTrials.gov NCT04184622. A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1). Eli Lilly and Company. clinicaltrials.gov
- International Committee of Medical Journal Editors. Recommendations: clinical trial registration. icmje.org
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PubMed 40756949
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.